June 21, 2022
Article
In an interview with Targeted Oncology, Roger Li, MD, discussed the use of the CG0070 in combination with pembrolizumab and nivolumab for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.
June 15, 2022
Article
Results from the phase 3 CLEAR trial showed lenvatinib plus everolimus to have a statistically significant improvement in progression-free survival and objective response rate compared with those given sunitinib.
June 07, 2022
Article
At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.
June 07, 2022
Article
At the 2022 ASCO Annual Meeting, results from the GEMSTONE-302 trial showed that adding sugemalimab to chemotherapy improved survival in patients with metastatic non–small cell lung cancer.
June 05, 2022
Article
At the 2022 ASCO Annual Meeting, the primary analysis of the phase 2 PILOT study showed the durability and feasibility of lisocabtagene maraleucel as second-line therapy in certain patients with large B-cell lymphoma.
May 23, 2022
Article
The European Society of Medical Oncology has announced the development of a new evidence-based classification framework to guide research and interpretation of data on the de-intensification of cancer treatments.